1. Home
  2. STTK vs APOG Comparison

STTK vs APOG Comparison

Compare STTK & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.30

Market Cap

683.8M

Sector

Health Care

ML Signal

HOLD

Logo Apogee Enterprises Inc.

APOG

Apogee Enterprises Inc.

HOLD

Current Price

$42.59

Market Cap

810.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
APOG
Founded
2016
1949
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
683.8M
810.1M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
STTK
APOG
Price
$7.30
$42.59
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$10.00
$47.00
AVG Volume (30 Days)
1.3M
157.8K
Earning Date
05-01-2026
04-24-2026
Dividend Yield
N/A
3.03%
EPS Growth
53.02
N/A
EPS
N/A
0.54
Revenue
$1,000,000.00
$1,404,733,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.07
P/E Ratio
N/A
$79.57
Revenue Growth
N/A
3.21
52 Week Low
$0.80
$30.75
52 Week High
$8.33
$50.88

Technical Indicators

Market Signals
Indicator
STTK
APOG
Relative Strength Index (RSI) 54.26 55.73
Support Level $5.87 $37.04
Resistance Level $7.75 $43.36
Average True Range (ATR) 0.52 1.24
MACD -0.03 0.15
Stochastic Oscillator 55.08 69.80

Price Performance

Historical Comparison
STTK
APOG

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.

Share on Social Networks: